Another early phase clinical trial (NCT03358719) is currently underway to investigate combination of decitabine with the NY-ESO-1 vaccine and nivolumab (anti-PD-1 mAb) in AML and MDS patients. The gene discussed is PDCD1; the disease is acute myeloid leukemia.